ChartMill assigns a Buy % Consensus number of 83% to BIVI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-07-01 | ThinkEquity | Initiate | Buy |
| 2023-11-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-17 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-02-14 | Oppenheimer | Reiterate | Outperform |
| 2022-09-28 | EF Hutton | Maintains | Buy |
| 2022-07-22 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-11-30 | B. Riley Securities | Maintains | Buy |
7 analysts have analysed BIVI and the average price target is 61.2 USD. This implies a price increase of 4433.33% is expected in the next year compared to the current price of 1.35.
The consensus rating for BIOVIE INC (BIVI) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.